<DOC>
	<DOCNO>NCT01676233</DOCNO>
	<brief_summary>Primary Objective : - To compare 24-hour glycemic profile continuous glucose monitoring ( CGM ) new formulation insulin glargine Lantus steady state Secondary Objectives : - To compare change Fasting plasma glucose ( FPG ) , Self-monitoring plasma glucose ( SMPG ) Postprandial Plasma Glucose ( PPG ) 2 treatment ; - To compare efficacy 2 treatment glycemic control glycemic parameter ( 1,5-anhydroglucitol hemoglobin A1c ( glycosylated hemoglobin ; HbA1c ) ) ; - To compare occurrence hypoglycemia 2 treatment ; - To assess safety tolerability new formulation insulin glargine .</brief_summary>
	<brief_title>Repeated Dose Study With New Insulin Glargine Formulation LantusÂ® 24-hour Glucose Profile Japanese Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>66 day</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Japanese patient Type 1 Diabetes Mellitus ( T1DM ) treatment basalbolus insulin ; Exclusion criterion : Age &lt; 20 year write informed consent ; HbA1c &lt; 6.5 % &gt; 10.0 % screen Diabetes mellitus ( DM ) T1DM ; Body Mass Index ( BMI ) &gt; 35.0 kg/m2 screen visit Any contraindication use insulin glargine define Japanese Package Insert Hypoglycemia unawareness history metabolic acidosis , include hospitalization diabetic ketoacidosis 24 week prior screen visit The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>